vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and WYNDHAM HOTELS & RESORTS, INC. (WH). Click either name above to swap in a different company.
WYNDHAM HOTELS & RESORTS, INC. is the larger business by last-quarter revenue ($334.0M vs $183.1M, roughly 1.8× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -18.0%, a 31.3% gap on every dollar of revenue. On growth, Amphastar Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-1.8% vs -76.3%). WYNDHAM HOTELS & RESORTS, INC. produced more free cash flow last quarter ($168.0M vs $24.6M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -4.6%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Wyndham Hotels & Resorts, Inc., is an American hospitality company based in Parsippany, New Jersey, United States. It describes itself as the largest hotel franchisor in the world, with 9,100 locations.
AMPH vs WH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $334.0M |
| Net Profit | $24.4M | $-60.0M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | — |
| Net Margin | 13.3% | -18.0% |
| Revenue YoY | -1.8% | -76.3% |
| Net Profit YoY | -35.7% | -170.6% |
| EPS (diluted) | $0.51 | $-0.80 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $334.0M | ||
| Q4 25 | $183.1M | $334.0M | ||
| Q3 25 | $191.8M | $382.0M | ||
| Q2 25 | $174.4M | $397.0M | ||
| Q1 25 | $170.5M | $316.0M | ||
| Q4 24 | $186.5M | $336.0M | ||
| Q3 24 | $191.2M | $396.0M | ||
| Q2 24 | $182.4M | $367.0M |
| Q1 26 | — | $-60.0M | ||
| Q4 25 | $24.4M | $-60.0M | ||
| Q3 25 | $17.4M | $105.0M | ||
| Q2 25 | $31.0M | $87.0M | ||
| Q1 25 | $25.3M | $61.0M | ||
| Q4 24 | $38.0M | $85.0M | ||
| Q3 24 | $40.4M | $102.0M | ||
| Q2 24 | $37.9M | $86.0M |
| Q1 26 | — | — | ||
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 19.4% | -11.4% | ||
| Q3 25 | 13.2% | 46.6% | ||
| Q2 25 | 24.2% | 37.8% | ||
| Q1 25 | 21.9% | 35.4% | ||
| Q4 24 | 24.2% | 38.4% | ||
| Q3 24 | 29.8% | 43.2% | ||
| Q2 24 | 30.3% | 39.5% |
| Q1 26 | — | -18.0% | ||
| Q4 25 | 13.3% | -18.0% | ||
| Q3 25 | 9.0% | 27.5% | ||
| Q2 25 | 17.8% | 21.9% | ||
| Q1 25 | 14.8% | 19.3% | ||
| Q4 24 | 20.4% | 25.3% | ||
| Q3 24 | 21.1% | 25.8% | ||
| Q2 24 | 20.8% | 23.4% |
| Q1 26 | — | $-0.80 | ||
| Q4 25 | $0.51 | $-0.77 | ||
| Q3 25 | $0.37 | $1.36 | ||
| Q2 25 | $0.64 | $1.13 | ||
| Q1 25 | $0.51 | $0.78 | ||
| Q4 24 | $0.74 | $1.06 | ||
| Q3 24 | $0.78 | $1.29 | ||
| Q2 24 | $0.73 | $1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $64.0M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $468.0M |
| Total Assets | $1.6B | $4.2B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $64.0M | ||
| Q4 25 | $282.8M | $64.0M | ||
| Q3 25 | $276.2M | $70.0M | ||
| Q2 25 | $231.8M | $50.0M | ||
| Q1 25 | $236.9M | $48.0M | ||
| Q4 24 | $221.6M | $103.0M | ||
| Q3 24 | $250.5M | $72.0M | ||
| Q2 24 | $217.8M | $70.0M |
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | $2.5B | ||
| Q3 25 | $608.6M | $2.6B | ||
| Q2 25 | $607.7M | $2.5B | ||
| Q1 25 | $603.9M | $2.5B | ||
| Q4 24 | $601.6M | $2.4B | ||
| Q3 24 | $596.4M | $2.4B | ||
| Q2 24 | $586.9M | $2.4B |
| Q1 26 | — | $468.0M | ||
| Q4 25 | $788.8M | $468.0M | ||
| Q3 25 | $776.7M | $583.0M | ||
| Q2 25 | $757.5M | $570.0M | ||
| Q1 25 | $751.3M | $579.0M | ||
| Q4 24 | $732.3M | $650.0M | ||
| Q3 24 | $727.7M | $583.0M | ||
| Q2 24 | $713.3M | $623.0M |
| Q1 26 | — | $4.2B | ||
| Q4 25 | $1.6B | $4.2B | ||
| Q3 25 | $1.7B | $4.3B | ||
| Q2 25 | $1.6B | $4.3B | ||
| Q1 25 | $1.6B | $4.2B | ||
| Q4 24 | $1.6B | $4.2B | ||
| Q3 24 | $1.5B | $4.2B | ||
| Q2 24 | $1.5B | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | 5.37× | ||
| Q3 25 | 0.78× | 4.43× | ||
| Q2 25 | 0.80× | 4.44× | ||
| Q1 25 | 0.80× | 4.29× | ||
| Q4 24 | 0.82× | 3.72× | ||
| Q3 24 | 0.82× | 4.19× | ||
| Q2 24 | 0.82× | 3.83× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $367.0M |
| Free Cash FlowOCF − Capex | $24.6M | $168.0M |
| FCF MarginFCF / Revenue | 13.4% | 50.3% |
| Capex IntensityCapex / Revenue | 4.5% | — |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $437.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $367.0M | ||
| Q4 25 | $32.9M | $152.0M | ||
| Q3 25 | $52.6M | $86.0M | ||
| Q2 25 | $35.6M | $70.0M | ||
| Q1 25 | $35.1M | $59.0M | ||
| Q4 24 | $29.0M | $134.0M | ||
| Q3 24 | $60.0M | $79.0M | ||
| Q2 24 | $69.1M | $1.0M |
| Q1 26 | — | $168.0M | ||
| Q4 25 | $24.6M | $136.0M | ||
| Q3 25 | $47.2M | $75.0M | ||
| Q2 25 | $25.0M | $58.0M | ||
| Q1 25 | $24.4M | $52.0M | ||
| Q4 24 | $16.6M | $109.0M | ||
| Q3 24 | $46.2M | $71.0M | ||
| Q2 24 | $63.1M | $-6.0M |
| Q1 26 | — | 50.3% | ||
| Q4 25 | 13.4% | 40.7% | ||
| Q3 25 | 24.6% | 19.6% | ||
| Q2 25 | 14.3% | 14.6% | ||
| Q1 25 | 14.3% | 16.5% | ||
| Q4 24 | 8.9% | 32.4% | ||
| Q3 24 | 24.1% | 17.9% | ||
| Q2 24 | 34.6% | -1.6% |
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 4.8% | ||
| Q3 25 | 2.8% | 2.9% | ||
| Q2 25 | 6.1% | 3.0% | ||
| Q1 25 | 6.3% | 2.2% | ||
| Q4 24 | 6.7% | 7.4% | ||
| Q3 24 | 7.2% | 2.0% | ||
| Q2 24 | 3.3% | 1.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 0.82× | ||
| Q2 25 | 1.15× | 0.80× | ||
| Q1 25 | 1.39× | 0.97× | ||
| Q4 24 | 0.76× | 1.58× | ||
| Q3 24 | 1.48× | 0.77× | ||
| Q2 24 | 1.82× | 0.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
WH
| Fee-related and other revenues | $334.0M | 100% |
| Management and other fees | $2.0M | 1% |
